Intellia Therapeutics (NTLA) Other financing activities (2017 - 2025)
Intellia Therapeutics (NTLA) posted quarterly Other financing activities of $625000.0 for Q4 2025, down 52.54% year-over-year from $1.3 million in Q4 2024, and up 154.82% quarter-over-quarter from -$1.1 million in Q3 2025.
Intellia Therapeutics (NTLA) Other financing activities (2017 - 2025) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Other financing activities for 9 consecutive years, with $625000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities fell 52.54% year-over-year to $625000.0; the TTM figure through Dec 2025 stood at $722000.0 (down 75.82% YoY), while the FY2025 annual figure was $722000.0, down 75.82% from the prior year.
- Other financing activities advanced to $625000.0 in Q4 2025 per NTLA's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Other financing activities topped out at $39.7 million in Q3 2021 and bottomed at -$13.1 million in Q2 2021.
- Historically, Other financing activities has averaged $3.5 million across 5 years, with a median of $1.2 million in 2021.
- On a YoY basis, Other financing activities climbed as much as 3870.24% in 2021 and fell as far as 3862.75% in 2021.
- Intellia Therapeutics' Other financing activities stood at $1.2 million in 2021, then jumped by 996.98% to $13.4 million in 2022, then plunged by 86.04% to $1.9 million in 2023, then slipped by 29.87% to $1.3 million in 2024, then slumped by 52.54% to $625000.0 in 2025.
- Business Quant data shows NTLA's Other financing activities at $625000.0 in Q4 2025, -$1.1 million in Q3 2025, and $1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 625,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Sep 30, 2025 | -1.14 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Jun 30, 2024 | -289,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Mar 31, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Sep 30, 2023 | 831,000.00 |
| Sep 30, 2023 | 831,000.00 |
| Jun 30, 2023 | 465,000.00 |
| Jun 30, 2023 | 465,000.00 |
| Mar 31, 2023 | 755,000.00 |
| Mar 31, 2023 | 755,000.00 |